US FDA approves Antisoma's oral fludarabine
This article was originally published in Scrip
Antisomahas received a boost to its licensing plans for its tablet formulation of its oral fludarabine product, in the form of a US FDA approval for the product as a second-line treatment for chronic lymphocytic leukaemia (CLL).
You may also be interested in...
Phase II results look good for one of the first-in-class product’s potential indications, C3 glomerulopathy. The product was highlighted late last year as an up-and-coming pipeline asset.
Positive Phase II data for Aptinyx’s novel NMDA receptor modulator are strong enough to take the product into a pivotal study in this difficult-to-treat area.
Orchard Therapeutics is on the cusp of the first approval for its ex vivo gene therapy, Libmeldy, for metachromatic leukodystrophy.